Both have partnered to use Pluristem’s patented PLacental eXpanded (PLX) cells on neurological indications, cardiovascular indications and comprehensive immunological research for Pluristem’s peripheral artery disease (PAD) clinical programs.
PAD programs are worth $16.5bn global market and have now entered into phase II trials, according to Pluristem.
Pluristem during the five year collaboration has also advanced in $24bn cardiovascular indications, which include ischemic heart disease and diastolic heart failure, both of which have completed pre-clinical trials.
As part of the extended agreement till 2017, BCRT and Pluristem will collaborate on Pluristem’s Phase I/II clinical trial in Germany to regenerate injured gluteal muscle and on immunological research and e development of new product candidates.
Pluristem chairman and CEO Zami Aberman said the PLX cells hold the key to a number of regenerative therapies and working with BCRT in the field of regenerative medicine is important to Pluristem.
"We look forward to further progress on indications in which we already have pre-clinical initiatives as well as discoveries in new indications," Aberman added.
BCRT director and chairman professor Hans Dieter Volk said both of them have had a productive collaboration over the past five years and are eager to continue into the future.
"We believe Pluristem’s cells can potentially result in beneficial therapies for a number diseases and together we can achieve significant breakthroughs in various indications."